CSL Shares Surge 16% as Investors Look Past Record Impairment Charge

CSL posts first statutory loss in 30 years due to $7.1B writedowns, but underlying profit beats estimates and shares jump 16%, signaling investor confidence.

Investors delivered a resounding vote of confidence in CSL on Tuesday, sending the Australian biotech group's shares sharply higher despite the company posting its first statutory net loss in more than three decades. The stock jumped 16 percent in pre-market trading to €96.37, with the market choosing to focus on underlying earnings that beat analyst expectations rather than the €7.1 billion in writedowns that pushed the books into the red.

The shares have now recovered substantially from their June lows, though they remain roughly 36 percent below the 52-week high of €150.56. The rebound reflects a growing acceptance among investors that the company's aggressive balance-sheet cleanup represents a necessary reset rather than a cause for alarm.

The Cost of the Vifor Acquisition

For the fiscal year ended June 30, CSL reported a statutory net loss of $2.6 billion, driven primarily by $7.1 billion in non-cash impairment charges and restructuring costs. The bulk of these writedowns relate to the company's 2022 acquisition of specialty pharmaceuticals group Vifor, with $5.5 billion of the total impairment recognized in the second half alone. Restructuring expenses added roughly $799 million to the damage.

Management has characterized the period as a "reset year," during which necessary strategic corrections were made. The heavy charges reflect the deteriorating outlook for Vifor, where generic competition is expected to drive a 25 percent decline in revenue in the coming year.

Underlying Strength Shines Through

Strip out the one-off items, however, and the picture looks considerably healthier. Underlying net profit after tax and amortization (NPATA) came in at approximately $3.1 billion, comfortably ahead of the consensus estimate of $3.05 billion that analysts at Macquarie had penciled in ahead of the results. Group revenue reached $15.8 billion.

The core CSL Behring division provided the main source of encouragement. Immunoglobulin sales held steady at $6.2 billion, with RBC Capital Markets highlighting 14 percent revenue growth in the segment during the second half. Albumin sales in China were a notable weak spot, falling 17 percent to $1.1 billion amid government cost-containment measures.

Newer products also contributed to the momentum. Gene therapy Hemgenix posted a 25 percent increase in sales, while the drug Andembry generated $250 million in revenue. The company's transformation program delivered $176 million in savings for the year, surpassing its own target.

A Confident Outlook and Capital Returns

Looking ahead to fiscal 2027, management has set an ambitious target of roughly 5 percent growth in underlying profit on a constant-currency basis — a forecast that significantly outstrips the market consensus of 0.7 to 2 percent growth. The plasma business is expected to remain the primary growth engine, with mid-single-digit percentage gains anticipated.

To underscore its confidence, CSL announced a new share buyback program worth A$1.1 billion, following the completion of a prior buyback of over A$1 billion during fiscal 2026. The final dividend was set at $1.62 per share, keeping the full-year payout steady at $2.92 per share. In a separate regulatory filing, BlackRock revealed it had increased its stake in the company from 5.1 percent to 6.3 percent.

Investment in the Future

Part of the turnaround strategy involves significant capital expenditure. The company has committed $1.5 billion to expanding its US plasma production network, including the "Horizon 2" program aimed at improving plasma yields. Following consultations with the FDA and the European Medicines Agency, the company confirmed last week that the new technology is slated to enter human clinical trials in mid-2027.

CSL has also been active on the partnership front. In early August, the group agreed to collaborate with Dutch biotech firm VarmX on developing a novel treatment to restore blood coagulation.

Analysts have responded favorably to the developments. Morgans reiterated its buy recommendation with a price target of A$147.59, identifying the stabilization of the CSL Behring plasma business as the key driver of the anticipated recovery. The company plans to increase its annual cost savings to $550 million by fiscal 2028, a trajectory that management believes will restore the group to its historical levels of profitability.